Guanhao Biotech Co.,Ltd. (SHE:300238)

Market Cap	4.35B
Revenue (ttm)	380.84M
Net Income (ttm)	27.89M
Shares Out	265.16M
EPS (ttm)	0.11
PE Ratio	155.42
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,206,000
Average Volume	23,388,236
Open	15.54
Previous Close	16.31
Day's Range	15.54 - 17.00
52-Week Range	8.09 - 18.38
Beta	0.85
RSI	57.45
Earnings Date	Aug 28, 2025

About Guanhao Biotech

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products primarily in China. It offers NormalGEN, a dura repair patch; GrandNeuro, a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 530
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300238

Financial Performance

In 2024, Guanhao Biotech's revenue was 377.48 million, a decrease of -6.60% compared to the previous year's 404.18 million. Earnings were 27.42 million, a decrease of -11.57%.